About BRIACELL THERAPEUTICS CORP
BriaCell is a clinical stage immuno-oncology company developing targeted cell-based immunotherapies to transform cancer care. Its lead candidate, Bria-IMT, has received Fast Track designation from the FDA and is in a pivotal Phase 3 study for metastatic breast cancer.
Development of targeted cell-based immunotherapiesPersonalized off-the-shelf immunotherapy platform (Bria-OTS)Clinical trials in metastatic breast cancer, prostate cancer, melanoma, and lung cancerHLA-matched immunotherapy using saliva testingCollaboration with the National Cancer Institute (NCI)
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to BRIACELL THERAPEUTICS CORP right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.